Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI
暂无分享,去创建一个
R Gieschke | R. Gieschke | P. Jacqmin | S Retout | P Jacqmin | I Delor | J-E Charoin | S. Retout | I. Delor | J. Charoin | Charoin Je
[1] Tim Schultz,et al. Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. , 2013, British journal of clinical pharmacology.
[2] Andrew C. Hooker,et al. Modeling Subpopulations with the $MIXTURE Subroutine in NONMEM: Finding the Individual Probability of Belonging to a Subpopulation for the Use in Model Analysis and Improved Decision Making , 2009, The AAPS Journal.
[3] Kaori Ito,et al. Disease progression meta-analysis model in Alzheimer's disease , 2010, Alzheimer's & Dementia.
[4] V. Lobanov,et al. An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative , 2012, Journal of clinical pharmacology.
[5] Mark E. Schmidt,et al. The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.
[6] A. Dale,et al. CSF Biomarkers in Prediction of Cerebral and Clinical Change in Mild Cognitive Impairment and Alzheimer's Disease , 2010, The Journal of Neuroscience.
[7] Mark E. Schmidt,et al. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.
[8] Terry L. Jernigan,et al. Changes in volume with age—consistency and interpretation of observed effects , 2005, Neurobiology of Aging.
[9] Nick C. Fox,et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease , 2009, Neurobiology of Aging.
[10] Keith A. Johnson,et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease , 2011, Alzheimer's & Dementia.
[11] Nick C Fox,et al. Hippocampal atrophy rates in Alzheimer disease , 2009, Neurology.
[12] Jieping Ye,et al. Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data , 2012, BMC Neurology.
[13] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[14] Mark E. Schmidt,et al. The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans , 2010, Alzheimer's & Dementia.
[15] Rudi Verbeeck,et al. Quantifying the pathophysiological timeline of Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.
[16] R. Tibshirani,et al. Generalized Additive Models , 1986 .
[17] Bruno Vellas,et al. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer’s disease trials , 2011, Alzheimer's & Dementia.
[18] Sébastien Ourselin,et al. Head size, age and gender adjustment in MRI studies: a necessary nuisance? , 2010, NeuroImage.
[19] Kaori Ito,et al. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database , 2011, Alzheimer's & Dementia.
[20] Joseph V. Hajnal,et al. A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T) , 2010, NeuroImage.
[21] J. Trojanowski,et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.